Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)-Reference-Cited by-同舟云学术

Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)

Published:2023-09-02 Issue:11 Volume:24 Page:515-525
ISSN:1527-2737
Container-title:Current Urology Reports
language:en
Short-container-title:Curr Urol Rep

Author:

Moyad Mark A.

Publisher

Springer Science and Business Media LLC

Subject

Urology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11934-023-01180-7.pdf

Reference103 articles.

1. Przegalinski E, Witek K, Wydra K, Kotlinska JH, Filip M. 5-HT2c receptor stimulation in obesity treatment: orthosteric agonists vs. allosteric modulators. Nutrients. 2023;15(6):1449. https://doi.org/10.3390/nu15061449.

2. Food & Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market: potential risk of cancer outweighs the benefits. Accessed 1 Jul 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market.

3. DiNicolantonio JJ, Chatterjee S, O’Keefe JH, Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart. 2014;1(1)e000173. https://doi.org/10.1136/openhrt-2014-000173.

4. Garcia-Fernandez G, Krotter A, Gonzalez-Roz A, Garcia-Perez A, Secades-Villa R. Effectiveness of including weight management in smoking cessation treatments: a meta-analysis of behavioral interventions. Addict Behav. 2023;140:107606. https://doi.org/10.1016/j.addbeh.2023.107606.

5. Tian J, Venn A, Otahal P, Gall S. The association between quitting smoking and weight gain: a systemic review and meta-analysis of prospective cohort studies. Obes Rev. 2016;17(10):1014. https://doi.org/10.1111/obr.12448.